Pharmaco-economics of blood transfusion safety: review of the available evidence. - Test2 - elhamkhani - TriplyDB

Pharmaco-economics of blood transfusion safety: review of the available evidence.

Pharmaco-economics of blood transfusion safety: review of the available evidence.

http://www.wikidata.org/entity/Q34803014

about

Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.Depletion of resident Chlamydia pneumoniae through leukoreduction by filtration of blood for transfusion.The challenge of an increasingly expensive blood system Cost-effectiveness of widespread screening for Chlamydia trachomatis.The Krever Commission--10 years later.The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions.Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients.Health technology assessment and haemophilia.Health economics and outcomes methods in risk-based decision-making for blood safety.Human T-lymphotropic virus and transfusion safety: does one size fit all?An inventory of concerns behind blood safety policies in five Western countries.Are there ethical differences between stopping and not starting blood safety measures?Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes.The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden.The outcome of donor screening for human T-cell lymphotropic virus infection in The Netherlands.Implementation of an intraoperative blood transport and storage initiative and its effect on reducing red blood cell and plasma waste.Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland.In vitro studies regarding the feasibility of bovine erythrocyte xenotransfusion.Solvent-detergent-treated plasma may be cost-effective.Cost-effectiveness of additional blood screening tests in the Netherlands.

P2860

Q30491951-CCCD63EA-9B07-46CE-AB80-92A3B717117E Q34042489-4FC86EF9-FEAD-440D-A048-8B107AF57E40 Q34963379-24D8E2A7-63E2-4789-A7AD-A28F98228C61 Q34974810-DF4A301B-5C3F-4493-A0B9-657B938A919C Q36131212-67F4C3A6-9585-4224-8192-51558DEE537B Q36831902-FFD2594B-E5D1-4935-B62A-4430AF394D1F Q37013124-C58EC229-FB9F-42FB-82E0-417CD63E6692 Q37062415-33D54A11-8368-45CF-9004-501D28C06C56 Q37083998-5E0F88F7-0C44-481B-9C21-80A362632E52 Q37136211-B7004CED-697F-42F2-8F7E-9AE235D85408 Q37984093-2CB7376A-8CDF-4479-A5B3-81D2B2B10C39 Q38412277-C9473A46-9A04-4B48-9FA0-406B6ED922F6 Q38590004-088D2F5E-A804-49AB-992E-FAE6C6072812 Q38968243-2E85277A-71AF-424E-8B24-02CE958881E2 Q40228627-FF3341E4-D082-41C2-A336-A75B9EC8F0DD Q40376149-7D5362D1-C8EC-4D11-A41D-C7033C350118 Q43000009-22C84F4E-46DC-4F5C-9813-ECDA7531B7D1 Q45363593-F20FD3B1-E2C5-4093-82B9-0453C9279486 Q46271077-5AC52A5E-CBB7-4D2C-B05C-09187D39E0B4 Q50513577-176D7177-5AFC-4E9D-9F77-6EDF801CCD83 Q51038154-A489033B-1377-4182-906A-ED36860895A0 Q51672615-896243D4-00F2-419E-8F24-4D042999C391 Q55239244-01C6194A-A7EB-4816-A364-B85F27C7EBA3

P2860

Pharmaco-economics of blood transfusion safety: review of the available evidence.

http://www.wikidata.org/entity/Q34803014

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@ast

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@en

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@nl

type

label

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@ast

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@en

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@nl

prefLabel

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@ast

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@en

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@nl

P1433

Q34803014-5E94BD2F-DD59-4C90-AAC2-D6CBBCDF3074

P1476

Q34803014-F5069912-2935-41FC-B27A-85E75896529D

P2093

Q34803014-4A540283-1B6D-435A-8AB8-477ED42C6517

Q34803014-5E5B9AA4-048B-48B0-9EE9-8971CD33478F

Q34803014-75E6BFF4-C89F-4AE0-AB52-F032B4C595C6

Q34803014-AE38F39B-2C67-4A4A-9D90-9B39AF652B73

Q34803014-D8832668-E89E-4BB4-BC33-D9A37BDEF2A8

P2860

Q34803014-0A340E0A-E2C3-4D7D-BB2D-2EE46B0277C0

Q34803014-2DC4703B-E443-403A-A9E5-7A19A9C3D07F

Q34803014-2FE1E24B-AAA0-471A-A123-27537419A3AD

Q34803014-3B2FF850-3A1C-4ABC-B9D7-92E8AA3CB3C7

Q34803014-3DC00C96-322E-4809-9A1F-1AF2A8AFAFFC

Q34803014-3E0CE7DE-15AA-42D8-98F2-73FEAC826FD2

Q34803014-42017E65-88A7-41B6-9C5C-CB6E2CA40B7F

Q34803014-47EDC860-3611-433B-B12C-D55353627CF4

Q34803014-59AD4AA6-667E-4AD5-BD7E-8F1C49D86ED1

Q34803014-5DDD57EE-E057-4654-9C67-296E1C9B1F2A

P304

Q34803014-ECAE5872-1C0B-462C-99B9-8E46AEC4AC18

P31

Q34803014-04235E16-F1AE-432C-A0CA-8DD873CC335A

P356

Q34803014-358EF1F6-08D5-40D6-861F-B727A98924F1

P433

Q34803014-96F5E9D7-FDD2-405E-BC32-E71943969FE7

P478

Q34803014-26FBDE8A-3CF3-4A71-9A57-855C123A7757

P577

Q34803014-36699E16-9BA0-47B3-9B5E-F68C0A8641F8

P698

Q34803014-AB0A4FE5-80C2-47FC-87A3-14DCF5474DF9

P356

J.1423-0410.2002.00198.X

P1433

P1476

Pharmaco-economics of blood transfusion safety: review of the available evidence.

@en

P2093

Postma MJ

http://www.w3.org/2001/XMLSchema#string

Ruitenberg EJ

http://www.w3.org/2001/XMLSchema#string

Staginnus U

http://www.w3.org/2001/XMLSchema#string

de Wolf JT

http://www.w3.org/2001/XMLSchema#string

van Hulst M

http://www.w3.org/2001/XMLSchema#string

P2860

Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study.

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.

Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis.

Hepatitis viruses and the safety of blood donations.

Five-hundred life-saving interventions and their cost-effectiveness.

Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective.

Evidence-based recommendations for the use of WBC-reduced cellular blood components.

Health economic guidelines--similarities, differences and some implications.

Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model.

Assessing the benefits of transplant services.

P304

146-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1423-0410.2002.00198.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12201844

http://www.w3.org/2001/XMLSchema#string